NCT05903833
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05903833
Title Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy (PIERCE)
Acronym PIERCE
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors AGO Research GmbH
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU

Facility Status City State Zip Country Details
Universitätsklinikum Augsburg NOT_YET_RECRUITING Augsburg Germany Details
Hochtaunus-Kliniken Bad Homburg NOT_YET_RECRUITING Bad Homburg Germany Details
Universitätsklinikum Carl Gustav Carus Dresden NOT_YET_RECRUITING Dresden Germany Details
Universitätsklinikum Düsseldorf NOT_YET_RECRUITING Düsseldorf Germany Details
KEM Kliniken Essen-Mitte RECRUITING Essen Germany Details
Universitätsklinikum Essen RECRUITING Essen Germany Details
Universitätsmedizin Göttingen NOT_YET_RECRUITING Göttingen Germany Details
University Hospital Hamburg RECRUITING Hamburg Germany Details
Klinikum Hanau GmbH RECRUITING Hanau Germany Details
ZAGO - Zentrum für ambulante gynäkologische Onkologie NOT_YET_RECRUITING Krefeld Germany Details
Universitätsmedizin Mainz NOT_YET_RECRUITING Mainz Germany Details
Universitätsklinikum Mannheim NOT_YET_RECRUITING Manheim Germany Details
Klinikum der Universität München, LMU NOT_YET_RECRUITING München Germany Details
Universitätsklinikum Münster NOT_YET_RECRUITING Münster Germany Details
University Hospital NOT_YET_RECRUITING Tübingen Germany Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field